Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 1/20 | 0.32 |
| ▸ | F2 | P00734 | 2/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.30 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL879554 | 0.91 | TAAR1 (0.34) | PTGESNPC1RAB9ATAAR1CNR1 | |
| SCHEMBL10287770 | 0.87 | TAAR1 (0.36) | F2NPC1RAB9ATAAR1CNR1 | |
| SCHEMBL16559047 | 0.85 | TAAR1 (0.33) | PTGESNPC1RAB9ATAAR1CNR1 | |
| SCHEMBL10079267 | 0.84 | PTGES (0.32) | PTGESF2 | |
| SCHEMBL16172321 | 0.81 | NOS1 (0.36) | PTGESCNR1 | |
| SCHEMBL10078124 | 0.80 | TAAR1 (0.45) | PTGESTAAR1 | |
| SCHEMBL13978409 | 0.80 | NPC1 (0.32) | F2NPC1RAB9ATAAR1CNR1 | |
| SCHEMBL15138993 | 0.77 | NOS1 (0.39) | F2 | |
| SCHEMBL16169716 | 0.76 | FFAR1 (0.33) | PTGESCNR1 | |
| SCHEMBL10079259 | 0.76 | TAAR1 (0.32) | TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120258141-A9 | Methods Of Immune Modulation | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2012-10-11 | — | — | US | disclosed |
| EP-2433627-A1 | Facially amphiphilic polymers and oligomers, compositions thereof, and use thereof in methods of treating cancer | The Trustees Of The University Of Pennsylvania (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20120039945-A1 | Methods Of Immune Modulation | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2012-02-16 | — | — | US | disclosed |
| EP-2301349-A2 | Facially amphiphilic polymers and oligomers, compositions thereof, and use thereof in methods of treating cancer | The Trustees of The University of Pennsylvania (US) | 2011-03-30 | — | — | EP | disclosed |
| WO-2010014573-A1 | ANTI-MALARIAL COMPOUNDS | POLYMEDIX, INC. (US) | 2010-02-04 | — | — | WO | disclosed |
| WO-2008083256-A2 | OPHTHALMIC AND OTIC COMPOSITIONS OF FACIALLY AMPHIPHILIC POLYMERS AND OLIGOMERS AND USES THEREOF | POLYMEDIX, INC. (US) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258141-A9 | Methods Of Immune Modulation | IFNG, CD14, TLR3 | PTGES 265/4885F2 2366/4885NPC1 1461/4885 |
| US-20120039945-A1 | Methods Of Immune Modulation | IFNG, CD14, TLR3 | PTGES 265/4885F2 2366/4885NPC1 1461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.